| 1. Add-on Clarithromycin and Tacrolimus Treatment for Rheumatoid Arthritis. |
Page:123—124 |
| 2. Aseptic Meningitis and Acute Kidney Injury after Immunoglobulin Infusion in a Patient with Systemic Lupus Erythematosus and Immune Thrombocytopenic Purpura. |
Page:119—122 |
| 3. Pulmonary Arterial Hypertension is Normalized Following Six Years of Inhaled Iloprost Treatment in a Patient with Systemic Sclerosis. |
Page:114—118 |
| 4. Rivaroxaban for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. |
Page:108—113 |
| 5. Meta-analysis of Circulating Adiponectin, Visfatin, and Ghrelin Levels in Patients with Systemic Lupus Erythematosus. |
Page:99—107 |
| 6. Does Painful Heels in Ankylosing Spondylitis Demonstrate Distinctive Features on Plain Radiographs: A Study of 104 Cases. |
Page:93—98 |
| 7. Urinary Tumor Necrosis Factor-like Weak Inducer of Apoptosis as a Biomarker for Lupus Nephritis: A Meta-analysis. |
Page:85—92 |
| 8. Radiotherapy, a New Treatment Option for Non-malignant Disorders: Radiobiological Mechanisms, Clinical Applications, and Radiation Risk. |
Page:74—84 |
| 9. The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus. |
Page:65—73 |
| 10. Risk Factors of Osteoporosis in Rheumatoid Arthritis Patients; Glucocorticoid, Inactivity, or Nutrient Deficiencies. |
Page:63—64 |
| 11. Radiotherapy, a New Treatment Option for Non-malignant Disorders: Radiobiological Mechanisms, Clinical Applications, and Radiation Risk. |
Page:74—84 |
| 12. The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus. |
Page:65—73 |
| 13. Risk Factors of Osteoporosis in Rheumatoid Arthritis Patients; Glucocorticoid, Inactivity, or Nutrient Deficiencies. |
Page:63—64 |
